Squarepoint’s Indivior Pharmaceuticals INDV Stock Holding History

Squarepoint’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,029	Closed	-$242K	–	4551
2025 Q3	$242K	Buy	+10,029	New	+$210K	﹤0.01%	3816
2025 Q2	–	Sell	-201,577	Closed	-$1.92M	–	4750
2025 Q1	$1.92M	Buy	+201,577	New	+$2.12M	﹤0.01%	2125

Other funds holding INDV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Squarepoint's INDV Position: Q4 2025 in Review

Squarepoint sold out of Indivior Pharmaceuticals (INDV) in Q4 2025, closing a stake of 10,029 shares — an estimated $242K sold.

Squarepoint first reported a position in INDV in Q1 2025 and held it in 2 quarters. The position peaked at $1.92M in Q1 2025. 259 funds tracked by Wall St. Rank hold INDV as of Q4 2025.

Squarepoint reported no remaining Indivior Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Squarepoint sold 10,029 Indivior Pharmaceuticals shares in Q4 2025, an estimated $242K.
Squarepoint first reported a position in Indivior Pharmaceuticals in Q1 2025 and held it in 2 quarters.
Squarepoint's Indivior Pharmaceuticals position peaked at $1.92M in Q1 2025.
259 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q4 2025.

Based on Squarepoint's 13F filing for Q4 2025, filed 13 Feb 2026.